Fibrodysplasia Ossificans Progressiva Clinical Trials

30 clinical trials for Fibrodysplasia Ossificans Progressiva across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• IL1 Inhibition in FOP — RECRUITING
• A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP) — RECRUITING
• To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva — RECRUITING · PHASE2
• The Fibrodysplasia Ossificans Progressiva (FOP) Registry — RECRUITING
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF INCB000928 IN PARTICIPANTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA — RECRUITING · PHASE2
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (PROGRESS) — TERMINATED · PHASE2
• A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase 2 study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participants. — OTHER · PHASE2
• Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability and Efficacy of Garetosmab in Patients with Fibrodysplasia Ossificans Progressiva — TERMINATED · PHASE3
• A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) — NOT_YET_RECRUITING · PHASE3
• A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). — TERMINATED · PHASE2
• An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP) — OTHER
• A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) — ACTIVE_NOT_RECRUITING · PHASE2
• A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP) — COMPLETED
• A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. — COMPLETED · PHASE3
• An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP) — COMPLETED · PHASE2
• Saracatinib Trial TO Prevent FOP — OTHER · PHASE2
• An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. — COMPLETED · PHASE3
• A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva — COMPLETED · PHASE2
• Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects — COMPLETED · PHASE1
• ROLLOVER STUDY; MULTICENTRE, PHASE III, OPEN-LABEL STUDY TO FURTHER EVALUATE THE SAFETY AND EFFICACY OF PALOVAROTENE CAPSULES IN MALE AND FEMALE PARTICIPANTS AGED ¿14 YEARS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) WHO HAVE COMPLETED STUDY PVO-1A-301 OR PVO-1A-202/PVO-1A-204 AND MAY BENEFIT FROM PALOVAROTENE THERAPY — COMPLETED · PHASE3
• An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families. — COMPLETED
• Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects — COMPLETED · PHASE1
• An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects — COMPLETED · PHASE2
• A PHASE 2, TWO-PART, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY ADN SAFETY OF 2 DOSAGE REGIMENS OF ORAL IPN60130 FOR THE TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA IN MALE AND FEMAL PARTICIPANTS 5 YEARS OF AGE AND OLDER — COMPLETED · PHASE2
• In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects — TERMINATED · PHASE2
• A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP) — COMPLETED
• A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA — NOT_YET_RECRUITING
• A PHASE 3, EFFICACY AND SAFETY STUDY OF ORAL PALOVAROTENE FOR THE TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP — COMPLETED · PHASE3
• Urine Sample Collection From FOP Patients — COMPLETED

Refine this search